Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2004
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Key products include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL. The company focuses on hematology, oncology, inflammation, metabolic, and bone disorders.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2004 |
Six Months Ended June 30, 2004 |
|---|---|---|
| Total Revenues | $2,584.9 | $4,927.9 |
| Product Sales | $2,431.0 | $4,638.8 |
| Operating Income | $1,006.7 | $1,934.8 |
| Net Income | $748.1 | $1,438.3 |
| Diluted EPS | $0.57 | $1.09 |
| Cash & Cash Equivalents | $1,716.9 | $1,716.9 |
| Marketable Securities | $2,544.9 | $2,544.9 |
| Total Debt (Current + Long-term) | $3,095.7 | $3,095.7 |
| Operating Cash Flow (6mo) | N/A | $1,513.8 |
Note: Debt consists primarily of $2.9 billion in Convertible Notes classified as current liabilities due to put options exercisable by holders starting March 1, 2005.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 27% for the three months and 30% for the six months ended June 30, 2004, compared to the same periods in 2003. Product sales grew 27% (QTD) and 31% (YTD).
- Profitability: Net income rose 23% for the quarter and 31% year-to-date. Operating income increased 23% (QTD) and 31% (YTD).
- Expense Increases: Total operating expenses increased 29% for the quarter and 29% year-to-date.
- R&D: Increased 19% (QTD) and 22% (YTD) due to higher staff and outside costs.
- SG&A: Increased 34% (QTD) and 35% (YTD) driven by staff costs and marketing expenses, including Wyeth profit share for ENBREL.
- Product Performance:
- Aranesp: Sales surged 78% (QTD) and 93% (YTD) driven by strong global demand.
- Neulasta: Sales grew 40% (QTD) and 46% (YTD), with international sales up 410% (QTD) following the 2003 European launch.
- ENBREL: Sales increased 45% (QTD and YTD) due to new psoriasis indication and rheumatology demand.
- NEUPOGEN: Sales declined 11% (QTD) and 8% (YTD) due to conversion to Neulasta and lower demand.
- Stock Repurchases: The company repurchased $1.65 billion of common stock in the first six months of 2004, compared to $900 million in the same period of 2003.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management expects near-term growth to be driven by Aranesp, Neulasta, and ENBREL. Capital expenditures for 2004 are estimated between $1.3 billion and $1.5 billion, focused on ENBREL manufacturing in Rhode Island and expansions in Puerto Rico and Thousand Oaks.
Material Risks and Contingencies
- Medicare Modernization Act (MMA): Significant uncertainty regarding reimbursement rates.
- Part B (Clinics): Effective Jan 1, 2005, reimbursement for Aranesp, NEUPOGEN, and Neulasta will shift to 106% of Average Sales Price (ASP). Initial ASP data suggests lower rates than current 2004 levels.
- Dialysis (EPOGEN): 2005 reimbursement rates are proposed to be 97% of ASP, a reduction from the current fixed rate. A final rule is expected by November 1, 2004.
- Part D (Prescription Drug Benefit): ENBREL, Sensipar, and Kineret may be covered starting Jan 1, 2006, potentially impacting pricing dynamics.
- Supply Constraints: ENBREL supply is dependent on third-party manufacturer Boehringer Ingelheim (BI Pharma) and fill/finish providers. Production yield variations could constrain sales. New capacity in Rhode Island, Genentech (South San Francisco), and Wyeth (Ireland) is planned but subject to regulatory approval.
- Patent Expirations: Key European patents for erythropoietin and G-CSF expire in late 2004 and mid-2006, respectively, potentially allowing biosimilar competition in Europe.
- Legal Proceedings:
- AWP Litigation: 15 civil actions and investigations by 11 states regarding alleged inflation of Average Wholesale Prices.
- Tularik Merger: Pending shareholder litigation regarding the proposed $1.5 billion acquisition of Tularik Inc.
Unusual Items
The prior year (2003) included a $74.0 million benefit from legal cost recovery related to a Johnson & Johnson arbitration and a $50.0 million charitable contribution to the Amgen Foundation. These items are not present in the current period.
Investor Verification Checklist
- Reimbursement Impact: Verify the final CMS rules regarding the MMA (Part B and Dialysis rates) expected in late 2004 and their quantitative impact on 2005 revenue.
- ENBREL Supply Chain: Monitor FDA approval status for new manufacturing facilities (Rhode Island expansion, Genentech, Wyeth Ireland) to ensure supply meets demand.
- Convertible Notes: Assess the company's liquidity strategy regarding the $2.9 billion Convertible Notes, which are callable by holders starting March 1, 2005.
- Patent Cliffs: Evaluate the competitive landscape in Europe following the expiration of erythropoietin and G-CSF patents in 2004 and 2006.
- Legal Exposure: Track developments in the Average Wholesale Price (AWP) litigation and the Tularik merger shareholder lawsuits.